A., de la Prez, J
These analogs represent promising candidates for therapeutic applications
Elimova E, Kim SM, Wang X, Shimodaira Y, Sohn BH, Skinner HD, Lee JH, Weston BR, Bhutani MS, Minsky B, Rice DC, Hwang JE, Swisher SG , Hofstetter W, Blum MA, Maru D, Ajani JA, Lee JS
Neurological Relevance Preclinical evidence suggests broader neuroprotective potential: In traumatic brain injury models, SS-31 reduced mitochondrial swelling, neuronal loss, and neuroinflammation Aged mice treated with SS-31 showed significantly improved exercise tolerance, muscle strength, and mitochondrial efficiency Studies demonstrate protection against ischemic injury and enhanced cardiac output Phase 3 trials are ongoing for dry age-related macular degeneration and primary mitochondrial myopathy (Stealth BioTherapeutics pipeline) Implications for Brain Aging Mitochondrial dysfunction is a hallmark of brain aging and neurodegeneration
Sierra, A